Akston Biosciences Corporation (AXTN)
Akston Biosciences will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$8.00 - $10.00
Shares Offered
2,222,222
Deal Size
$20.00M
Company Description
Akston Biosciences is a pet biotechnology company focused on the development and commercialization of innovative biopharmaceutical products for cats, dogs, and other companion animals.
Our current product portfolio includes multiple product candidates consisting of large molecule biologics that are designed to target significant opportunities in serious medical conditions in pets such as urothelial carcinoma (bladder cancer) in dogs, atopic dermatitis in dogs, chronic pain associated with arthritis in dogs, and obesity and metabolic disease in cats.
Akston Biosciences Corporation
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Todd C. Zion, Ph.D. |
Contact Details
Address: 100 Cummings Center, Suite 454C Beverly, MA 01915 United States | |
| Phone | (978) 969-3381 |
| Website | akstonbio.com |
Stock Details
| Ticker Symbol | AXTN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001776612 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd C. Zion, Ph.D. | President, Chief Executive Officer, Director and Chairman of the Board |
| Thomas M. Lancaster, Ph.D. | Vice President, Manufacturing and Product Research and Development, and Director |
| James Herriman | Vice President, Operations and Chief Financial Officer |
| Thillainayagam Sathiyaseelan, Ph.D. | Vice President, Quality and Regulatory Affairs |
| Lovick E. Cannon, Ph.D. | Director |
| Robyn C. Davis | Director |
| Linda Rhodes, VMD, Ph.D. | Director |
| Rahul Bhansali | Director |
| Michael Hall | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 8, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 19, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 25, 2025 | DRS | [Cover] Draft Registration Statement |
| Apr 15, 2022 | D | Notice of Exempt Offering of Securities |
| Jun 9, 2021 | D/A | Filing |
| Jun 1, 2021 | D | Notice of Exempt Offering of Securities |
| Dec 30, 2020 | D | Notice of Exempt Offering of Securities |
| May 12, 2020 | D | Notice of Exempt Offering of Securities |
| Jun 20, 2019 | D | Notice of Exempt Offering of Securities |